We are a pharmaceutical start-up focusing on bringing new cannabinoid therapeutics for the treatment of chronic pain, anxiety, and seizure disorders to market.

The Agrithera Solution

Agrithera’s unique CBD technology positions the company to bring new, FDA-approved CBD therapeutics for the treatment of pain, anxiety, and other disorders.

The Market Opportunity

The abuse of opioids has created global crisis of monumental proportions. The need to address this crisis with a non-addictive alternative therapeutic is clear. CBD holds promise to be that alternative. And the market for such a therapeutic is enormous.

Dennis C. Liotta, PhD (Founder and Director)

Dennis C. Liotta, PhD (Founder and Director) Through his discoveries, Dr. Liotta has helped to transform HIV/AIDS from a death sentence to a chronic infection in which patients are able to live active, near normal lives. Over ninety per cent of HIV-infected patients in the United States have taken one of the two drugs he invented: lamivudine (Epivir) and emtricitabine (Emtriva). Dr. Liotta’s contributions to improving human health are not restricted to AIDS: (a) he co-discovered lamivudine (Epivir-HBV), the first drug approved by the FDA for hepatitis B (HBV) infections; and (b) he co-founded Pharmasset (acquired by Gilead Sciences in 2012), which developed sofosbuvir (Sovaldi), the breakthrough drug for hepatitis C infection (HCV). In addition, he has founded numerous other companies including Triangle Pharmaceuticals (acquired by Gilead Science), QUE Oncology, NeurOp, and DRIVE (Drug Innovation Ventures at Emory). Dr. Liotta has authored over 295 peer reviewed publications and is an inventor on over 95 issued US patents. He has been inducted into the National Academy of Inventors for his contributions to drug discovery and development, as well as to the ACS (American Chemical Society) Medicinal Chemistry Hall of Fame.

John P. Richard (Director)

John Richard is Co-Founder and Head of Corporate Development of Mereo BioPharma Group, plc. (NASDAQ: MREO). He has significant corporate, operational and transactional experience, having served in various executive, director and advisory roles throughout his career. Prior to Mereo he was an Operating Partner with Phase4 Ventures and a Partner with Georgia Venture Partners. Previously, he was Executive VP Business Development at SEQUUS, where he was responsible for negotiating SEQUUS’ acquisition by ALZA. Mr. Richard also headed business development for VIVUS and Genome Therapeutics; where he established numerous alliances. Mr. Richard received his M.B.A. from Harvard Business School and his B.S. from Stanford University.

Jennifer Liotta (CEO and Director)

This is a sample text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus eu placerat quam. Morbi aliquet faucibus convallis. Maecenas id tincidunt lectus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam vehicula diam eget efficitur rutrum. Mauris bibendum lacus non scelerisque rutrum. Morbi odio ligula, commodo at lacus ullamcorper, aliquet lacinia enim. Phasellus consequat augue et nisl aliquet, a bibendum sapien volutpat. Curabitur at ante vel ipsum sollicitudin condimentum sit amet in lacus.

Stephen Traynelis, PhD (Founder)

Stephen Traynelis, Ph.D., is a professor of pharmacology at the Emory University School of Medicine (Atlanta, GA). He has made numerous seminal discoveries about the fundamental properties of glutamate receptors. Dr. Traynelis was elected an AAAS Fellow in 2014, served as Editor-in-Chief of in Molecular Pharmacology from 2012-16, and is a recipient of a NIH Javits Award and R35 Research Program Award. He is a co-author on over 200 peer-reviewed papers, book chapters, and invited commentaries, has trained over 100 under graduates, graduate students, postdoctoral fellows, residents, and international students. Dr Traynelis is a co-inventor on 7 issued US patents. Dr. Traynelis received his PhD from the University of North Carolina and postdoctoral fellowships from University College London and the Salk Institute.

Email: info@agrithera.com

Agrithera © Copyright 2020 - All Rights Reserved

Share this: